Differential stability of antigenic MHC class I-restricted synthetic peptides.
Various synthetic peptides recognized as Ag by CTL in the context of MHC class I molecules were tested for stability in vitro and in vivo. Peptide inactivation in vitro was quantitated by titrating the amount of peptide required to sensitize target cells for lysis by specific CTL clones. The degree of inactivation after overnight incubation at 37 degrees C varied widely among a series of antigenic peptides. Some were nearly unaffected, whereas others lost activity by more than 100-fold or even 10,000-fold. However, no correlation was found between susceptibility to serum inactivation and antigenic potency as measured in short term cytolytic assays. No inactivation occurred at 4 degrees C, or at 37 degrees C in the absence of serum, under the conditions used. Serum inactivation most likely involved proteolysis because it could be inhibited by protease inhibitors. Moreover, presumed cleavage products of a radiolabeled susceptible peptide could be visualized by TLC. In vivo, the persistence of the antigenic activity of the injected peptides, either in extracellular fluids or on tumor target cells growing in an ascites form, correlated with the degree of stability found for the peptides in vitro. The differential stability of synthetic peptides may have important consequences for attempts to manipulate the development of an immune response in vivo.
Institute of Biochemistry, University of Lausanne, Epalinges, Switzerland.
C
C
Widmann
J L
JL
Maryanski
P
P
Romero
G
G
Corradin
D000595:Amino Acid Sequence; D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D001202:Ascitic Fluid / Q000378:metabolism; D002999:Clone Cells; D003470:Culture Media; D006680:HLA Antigens / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000502:physiology*; D066298:In Vitro Techniques; D051379:Mice; D008969:Molecular Sequence Data; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins; D010455:Peptides / Q000276:immunology / Q000378:metabolism* / Q000493:pharmacokinetics; D011480:Protease Inhibitors / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014758:Viral Core Proteins / Q000276:immunology
D000953:Antigens, Protozoan; D003470:Culture Media; D006680:HLA Antigens; D000949:Histocompatibility Antigens Class II; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins; D010455:Peptides; D011480:Protease Inhibitors; D014758:Viral Core Proteins